Zydus Cadila Receives Us Fda Tentative Approval For Dapagliflozin & Linagliptin Tablets

Zydus Cadila Has Received Tentative Approval From The Us Fda To Market Dapagliflozin Tablets, 5 Mg And 10 Mg.Dapagliflozin Is A Sodium-Glucose Cotransporter 2 (Sglt2) Inhibitor Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus And To Reduce The Risk Of Hospitalization For Heart Failure In Adults With Type 2 Diabetes Mellitus And Established Cardiovascular Disease Or Multiple Cardiovascular Risk Factors.Zydus Cadila Is Believed To Be The Only Company With Tentative Approval That Has Submitted A Paragraph Iv Certification For Us Patent No. 6,515,117 That Claims The Dapagliflozin Compound. The Us District Court For The District Of Delaware Has Scheduled A Trial In February 2021 Regarding Zydus Cadila'S Patent Challenge.The Drug Will Be Manufactured At The Group'S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Company Has Also Received Tentative Approval From The Us Fda To Market Linagliptin Tablets, 5 Mg. Linagliptin Is A Dipeptidyl Peptidase-4 (Dpp-4) Inhibitor Indicated As An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus.The Drug Will Be Manufactured At The Group'S Formulation Manufacturing Facility At The Sez, Ahmedabad.The Group Now Has 311 Approvals And Has So Far Filed Over 390 Andas Since The Commencement Of The Filing Process In Fy 2003-04

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!